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Oxidative stressonly known DNA polymerase in human mitochondria and is essential for
mitochondrial DNA replication and repair. It is well established that defects in mtDNA replication lead to
mitochondrial dysfunction and disease. Over 160 coding variations in the gene encoding the catalytic subunit
of DNA polymerase γ (POLG) have been identiﬁed. Our group and others have characterized a number of the
more common and interesting mutations, as well as those disease mutations in the DNA polymerase γ
accessory subunit. We review the results of these studies, which provide clues to the mechanisms leading to
the disease state.
Published by Elsevier B.V.1. IntroductionMitochondria have their own small 16.5 kb circular double-
stranded DNA that encodes 22 tRNAs, 2 rRNAs and 13 polypeptides
that are absolutely essential for electron transport and oxidative
phosphorylation. Nuclear genes encode the other 1000–1500 proteins
that are imported into the mitochondria [1]. These include the
proteins involved inmitochondrial DNA (mtDNA) replication, which if
defective can produce mtDNA mutations leading to mitochondrial
dysfunction and disease [2] (Fig. 1).
MtDNA is replicated by an assembly of proteins and enzymes
including DNA polymerase γ (pol γ) and its accessory protein, single-
stranded DNA binding protein (mtSSB), mtDNA helicase (Twinkle),
and a number of accessory proteins and transcription factors
(reviewed in [3]). The minimal proteins needed for in vitro mtDNA
replication include the two subunit pol γ, the mitochondrial helicase
and mtSSB [4]. Two modes of DNA replication have been proposed, an
asynchronous strand displacement model and a strand-coupled
bidirectional replication model (reviewed in [5]). In the asynchronous
strand displacement model mtDNA is replicated in an asymmetricogressive external ophthalmo-
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B.V.fashionwhere DNA synthesis is primed by transcription through the H
strand origin within the D-loop [6]. After two-thirds of the nascent H
strand is replicated, the L strand origin is exposed, allowing initiation
of nascent L strand synthesis. In the strand-coupled model bidirec-
tional replication is initiated from a zone near OriH followed by
progression of the two forks around the mtDNA circle [7]. In both
models the DNA polymerization reaction is performed by pol γ.
Of the 16 DNA polymerases in the eukaryotic cell, only pol γ is
known to function in the mitochondria [8–10]. The holoenzyme of
human pol γ consists of a catalytic subunit (encoded by POLG at
chromosomal locus 15q25) and a homodimeric form of its accessory
subunit (encoded by POLG2 at chromosomal locus 17q24.1) [11]. The
catalytic subunit is a 140 kDa enzyme (p140) that has DNA
polymerase, 3′–5′ exonuclease and 5′ dRP lyase activities. Alignments
reveal that the catalytic subunit sequence is well conserved across
species, with all genes containing conserved sequence motifs for DNA
polymerase and 3′–5′ exonuclease functions (Fig. 2). The accessory
subunit is a 55 kDa protein (p55) required for tight DNA binding and
processive DNA synthesis [12]. In 2001, the ﬁrst disease mutations
were identiﬁed in POLG [13]. These mutations were associated with
progressive external ophthalmoplegia (PEO). Subsequently, muta-
tions in POLG were identiﬁed in patients with Alpers syndrome and
other infantile hepatocerebral syndromes, ataxia–neuropathy syn-
dromes, Charcot–Marie–Tooth disease, idiopathic parkinsonism,
nucleoside reverse-transcriptase inhibitor (NRTI) toxicity, among
others (for review see [2,3,14]). These diseases are characterized by
mtDNA deletions or depletion in symptomatic tissues. To date,
approximately 150 disease mutations in POLG have been identiﬁed,
which places POLG as a major locus for mitochondrial disease (http://
tools.niehs.nih.gov/polg/) (Fig. 3). POLG2 mutations associated with
Fig. 1. The mitochondrion and some of the enzymes involved in mtDNA replication or nucleotide metabolism. Mutations in some of these genes (green boxes) are associated with
mtDNA depletion or mutations in humans.
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others have been motivated to determine how mutations in both
subunits of pol γ cause disease. Here is a comprehensive review of
what is currently understood from experimental studies.
2. POLG mutations associated with autosomal dominant
mitochondrial disease
PEO is the only mitochondrial disease that has cosegregated with
autosomal dominant (ad) mutations in POLG. Nearly all of the adPEO
mutations in POLG are located in the polymerase domain of pol γ (Fig.
4). One of the ﬁrst adPEO mutations to be discovered was the Y955C
mutation [13], and this was also the ﬁrst to be biochemically
characterized [16]. We found the Y955C p140 to be a mutator, causing
a 10- to 100-fold increase in misinsertion errors, most likely as a
consequence of a 45-fold decrease in binding afﬁnity for the incoming
nucleoside triphosphate. This enhanced mutagenesis is mitigated by a
functional intrinsic exonuclease activity resulting in only a 2-fold
mutator effect for base pair substitutions by the exonuclease-
proﬁcient Y955C enzyme. In a subsequent study of four adPEOmutantFig. 2. Schematic linear organization of the pol γ catalytic subunit with conserved domains. T
and III while the DNA polymerase domains (green) are encoded by the three ABC motifs.p140 variants, the Y955C and R943H substitutions were predicted to
interact directly with the incoming dNTP by analysis of a structural
model of the polymerase active site based upon the solved crystal
structure of T7 DNA polymerase [17]. Recombinant proteins carrying
these substitutions retain less than 1% of the wild-type (WT)
polymerase activity and display a severe decrease in processivity.
The signiﬁcant stalling of DNA synthesis and extremely low catalytic
activities of both enzymes are the twomost likely causes of the severe
clinical presentation in R943H and Y955C heterozygotes [17]. The
G923D and A957S p140 proteins retained less than 30% WT
polymerase activity. This is consistent with the reduced clinical
severity of PEO in individuals heterozygous for the G923D and A957S
mutations [17].
In a genetic model developed to evaluate the homologous PEO
mutations in the yeastMIP1 gene, we studied Y757C (Y955C in human
POLG), as well as L260R (human L304R), I416T (human A467T),
G725D (human G923D), R745H (human R943H), and A759S (human
A957S) in Saccharomyces cerevisiae [18]. The amino acid codon
changes were made directly into the chromosomal MIP1 gene by de-
litto perfetto site-directed mutagenesis. The L260R, G725D, R745H andhe conserved 3′–5′ exonuclease domains (orange) are encoded by the three motifs I, II,
Fig. 3. POLG disease mutations and polymorphisms (modiﬁed from http://tools.niehs.nih.gov/polg/).
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result of mtDNA depletionwhile only the R745H and Y757Cmutations
showed dominant petite frequency in diploid cells. The A759S
mutation produced 35% petites in haploid yeast with no appreciable
increases in diploid cells, which suggests this mutation is not
dominant in yeast. Interestingly, the Y757C mutation demonstrated
enhanced mtDNA damage indicative of oxidative damage and over
80% petites in the diploid strain [18]. In a related study, Barufﬁni et al.
reported that this high petite frequency could be rescued by treatment
with a reactive oxygen species (ROS) scavenger (dihydrolipoic acid) or
up-regulation of ribonucleotide reductase (RNR1, another mitochon-
drial disease locus, Fig. 1) [19]. The reduction of petite formation by
up-regulation of dNTP pools via RNR overexpression is predicted
based on the lower afﬁnity for dNTPs by this enzyme. However, the
reversal of the high petite phenotype by dihydrolipoic acid and the
enhanced mtDNA oxidative damage suggests a role of oxidative stress
with the Y955C mutation.
An increase in mitochondrial ROS, as shown by an increase in the
marker, 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) in mtDNA,
was also seen in a transgenic mouse study, the ﬁrst mouse study
involving a bona ﬁde POLG disease mutation [20]. Y955C POLG was
targeted to mouse hearts, which lead to multiple markers of
mitochondrial dysfunction, such as mtDNA depletion, and ultrastruc-tural changes in mitochondria with damaged cristae. Increased ROS
and mitochondrial dysfunction gave rise to a number of cardiac
defects, such as cardiomegaly, biventricular dilation, increased left
ventricular mass and cardiac rhythm disturbances, ultimately causing
premature death. These results indicate that oxidative damage to
mtDNA may be part of the pathological mechanism associated with
the Y955C mutation.
The association of oxidative damage and the Y955C enzyme was
investigated biochemically and structurally by assaying the ability
of WT and Y955C p140 to incorporate 8-oxo-dGTP or replicate past
an 8-oxo-dG lesion in DNA [21]. The 8-oxo-dG base can form two
conformations in DNA, the anti-conformation, which favors Wat-
son–Crick base pairing with dCMP, and the syn-conformation,
which allows mutagenic Hoogsteen base pairing with dAMP. Pol γ
normally prevents mutagenesis by 8-oxo-dG through interactions
from Tyr955 and Phe961, which limit the syn-conformation of the
8-oxo-dG template base during translesion DNA synthesis. However
substitution of Tyr955 with Cys allows signiﬁcantly more muta-
genic syn-conformation and causes the polymerase to display
relaxed discrimination when either incorporating 8-oxo-dGTP onto
the primer-terminus or translesion synthesis opposite 8-oxo-dG in
the template strand [21]. Collectively, these studies suggest that
patients harboring the Y955C mutation may have elevated
Fig. 4. POLG disease mutations and their location within the structural homology model of the polymerase domain of pol γ against the solved crystal structure of T7 DNA
polymerase [17].
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sion of disease.
3. The most common POLG disease mutation
The A467T mutation has been found in all of the major POLG-
related diseases, i.e. Alpers syndrome, ataxia–neuropathy syndromes
and PEO. The frequency of the A467T mutation is approximately 0.6%
in the Belgian control population [13], 0.69% in the British control
population [22], 1% in the Norwegian control population [23], and less
than 0.2% in 380 Finnish controls [24]. However, in mitochondrial
disease populations, the A467T allele is estimated to occur in 36% of all
alleles associated with POLG disease, as shown by ﬁve large
mitochondrial disease population studies identifying POLG mutations
[22, 25–28]. These frequencies make A467T the most common disease
mutation in POLG.
We characterized the recombinant pol γ containing the A467T
mutation puriﬁed from baculovirus-infected insect cells. A467T p140
had poor polymerase activity, with only 4% activity compared to WT
enzyme. This was due to a greater than 5-fold decrease in kcat and a
4.7-fold increase in Km(dNTP). Additionally, exonuclease activity was
reduced 2-fold compared to WT [29]. The A467T p140 showed poor
DNA binding in an electrophoretic mobility shift assay, with a 5-fold
increase in Kd compared to WT. Strikingly, the A467T mutation
rendered the p140 enzyme poorly able to bind to the p55 accessory
subunit, as shown by immunoprecipitation experiments, processivity
and primer extension assays. Furthermore, the p55 accessory subunit
was unable to protect the A467T p140 catalytic subunit from N-
ethylmaleimide [29]. Thermolysin digestion experiments of WT and
A467T p140 revealed quite different digestion proﬁles. The p55
accessory subunit protected an 80 kDa fragment of WT p140 that was
degraded in the absence of the p55 accessory subunit, whereas there
were no signiﬁcant differences in the A467T p140 digestion proﬁles,
either with or without p55. Collectively, these results demonstrate the
poor interaction of A467T p140with the accessory subunit. Luoma and
colleagues also characterized recombinant p140 containing the A467T
substitution [24]. This A467T mutant enzyme showed decreasedpolymerase activity, poor DNA binding and poor primer extension,
however stimulation by p55 was observed.
A467T mutation is generally reported as a recessive mutation,
however it was suggested that A467Tmaygive rise to amild dominant
phenotype causing late-onset ptosis [24]. Solid-phase mini-sequen-
cing was used to determine gene expression levels of the two alleles.
A467T POLG gene expressionwas slightly lower (40%) than that of the
WT POLG allele (60%), suggesting that therewas no expression bias for
theA467Tallele [24]. Yeastmodels ofmitochondrial disease canhelp to
determine the contribution of both alleles to disease phenotype, and
are especially helpful for verifying dominant or recessive mutations of
interest. Although this region is not well conserved in S. cerevisiae,
studies revealed that the yeast homolog of the human A467T pol γ
mutation, I416T inMip1, is recessive [18]. Interestingly, I416TMip1 had
signiﬁcantly elevated levels of both mitochondrial and nuclear DNA
damage, as measured by the QPCR method [18].
4. Nonsense mediated decay of transcripts containing a premature
termination codon
There are more than 10 mutations in POLG that produce a
premature termination codon (PTC), a frameshift or an alternative
spliced transcript (Fig. 2). The ﬁrst POLG mutations (A467T and
E873X) associated with Alpers syndrome were identiﬁed in 2004
in two unrelated pedigrees [30, 31]. We studied the skin ﬁbroblasts
of one patient whose POLG genotype was E873X/A467T [32]. The
allele containing the E873X mutation in exon 17 was expected to
produce a truncated protein. However, only full-length p140
protein was detected by Western blot analysis. Sequence analysis
of the cDNA from the pre-spliced message showed that both alleles
were represented. However, upon sequencing the cDNA from the
mature message, only transcripts containing the A467T mutation
were found. Thus, full-length p140 arose from the allele containing
the A467T mutation. Further analysis revealed that message arising
from the E873X allele were degraded by the nonsense-mediated
mRNA decay pathway (NMD) [32]. The NMD pathway degrades
transcripts containing PTCs that are at least 50–55 nucleotides
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showed an increase in transcripts containing the PTC. Ampliﬁcation
of the region ﬂanking exon 17 revealed a smaller, faint band in
patient cells, but not in normal foreskin ﬁbroblasts. Sequencing
showed that exon 17 had been skipped by the nonsense-associated
alternative splicing pathway (NAS), which produces a frameshift
leading to another PTC. Thus, both the NMD and NAS pathways
were involved. Virtually all mRNAs produced from the allele
containing the PTC were destroyed by the NMD and NAS
mechanisms. Thus, the severity of disease for this patient is most
likely due to mono-allelic expression of A467T p140 [32].
Extrapolating to other mutations of this nature, NMD and NAS
are expected to remove those POLG mRNAs containing PTCs.
5. The contribution of POLG polymorphisms to mitochondrial
disease
Luoma and colleagues studied the contribution of the Q1236H
polymorphism to the disease in patients with the POLG genotype
A467T/R627Q-Q1236H [24]. Q1236H occurs in Caucasian populations
at a frequency of 3.7%, however a much higher frequency (14.8%) in
Finnish controls was observed [24]. Luoma et al. characterized pol γ
p140 proteins containing each of these three mutations, as well as
R627W. R627W has been associated with recessive mitochondrial
disease, whereas R627Q may be a dominant POLG mutation. The
R627Q and R627W p140 proteins had similar DNA binding properties
compared to WT and were equally stimulated by the accessory
subunit. R627Q had a slightly lower polymerase activity (77%).
Interestingly, both R627Q-Q1236H p140 and Q1236H p140 had
greater polymerase activity than WT (151% and 117% respectively),Table 1
Summary of experimental data on DNA polymerase γ disease variants#
Human mutation Yeast mutation Human disease Bioc
(CAG)n n.h.a Male infertility, testicular cancer, Parkinson's
disease
G268A G244A arPEO
L304R L260R arPEO
A467T I416T Alpers syndrome, ANS, PEO Defe
4% c
bind
R627Q n.h. PEO, ANS 77%
W748S n.h. Alpers syndrome, ANS, PEO Defe
and
G848S G651S Alpers syndrome, PEO Redu
E873X E676 Alpers syndrome
A889T A692T PEO Redu
G923D G725D adPEO 21%
H932Y H734Y PEO, ataxia Redu
R943H R745H adPEO 0.2%
high
Y955C Y757C adPEO, parkinsonism 0.03
Mut
A957S A759S adPEO 23%
R964C n.h. NRTI toxicity Redu
G1051R G807R PEO, ataxia Sligh
E1143G E900G Polymorphism, 4% in population 1.4-f
Q1236H n.h. Polymorphism, 3.7% in population High
ANS = ataxia–neuropathy syndromes; arPEO = autosomal recessive PEO.
#References for data contained in this table can be found in the text.
a Not homologous in yeast.which may be a consequence of their signiﬁcantly higher DNA
binding.
The E1143G polymorphism is found in 4% of the general
population and is also linked with many alleles containing known
disease mutations. Thus, it has been unclear as to whether E1143G
is a neutral polymorphism. The W748S mutation is the most
common mutation in ataxia–neuropathy spectrum disorders and
has also been associated with Alpers syndrome [33]. The W748S
mutation is generally found in cis with E1143G. To investigate the
contributions of both mutations, we biochemically characterized
pol γ p140 proteins containing W748S, E1143G, or both [34].
W748S p140 exhibited low DNA polymerase activity, low proces-
sivity and a severe DNA-binding defect. Interactions between the
W748S p140 and the p55 accessory subunit were normal, but did
not rescue the catalytic defect. Surprisingly, E1143G p140 was 1.4-
fold more active than WT. The E1143G substitution partially
rescued the deleterious effects of the W748S mutation, as DNA
binding, catalytic activity and ﬁdelity values were greater for
W748S-E1143G p140 than W748S p140. However, W748S-E1143G
p140 had a notably lower change in enthalpy for protein folding
than W748S alone, suggesting that E1143G does not confer a purely
beneﬁcial effect to the double mutant. In light of these results,
E1143G and Q1236H when in cis with pathogenic mutations may
modulate the effects of the pathogenic mutations.
Barufﬁni and colleagues studied the A692T Mip1 polymerase
domain mutation (A889T in human POLG) in S. cerevisiae with
and without Mip1 E900G (E1143G in human POLG) [35]. In yeast,
A692T Mip1 had low speciﬁc gap-ﬁlling activity (29–30%
compared to WT) and signiﬁcantly increased mtDNA instability.
Similar to what was observed with the recombinant E1143G polhemical data Genetic data
No defect in mtDNA detected in human cells
transfected with POLG-deleted CAG repeat.
2.5-fold increase in petite frequency in yeast.
10-fold increase in point mutations (haploid yeast)
100% petites in haploid yeast, 7.9% in diploid
ct in accessory subunit binding.
atalytic activity due to low DNA
ing, low kcat, high Km.
Causes mtDNA and nuclear DNA damage in yeast,
9% petites as haploid yeast.
polymerase activity
ct in catalysis, DNA binding,
enzyme stability.
Nearly always occurs with the E1143G mutation.
ced gap-ﬁlling activity 46% petites in haploid yeast and high mutation
frequency.
Stop codon leads to nonsense mediated decay
of message, and pseudo monoallelic expression
of other POLG allele
ced gap-ﬁlling activity 17% petite frequency in haploid yeast
polymerase activity 100% petites in haploid yeast, only 7.6%
in diploid.
ced gap-ﬁlling activity Nearly 100% petites in haploid yeast
polymerase activity due to
Km(dNTP) and lower kcat.
100% petites in haploid yeast, 37% in diploid yeast.
Loss of mtDNA in yeast.
% polymerase catalytic activity.
ator polymerase
Loss of mtDNA in transgenic mice, oxidative stress,
cardiomyopathy.
High petite frequency in yeast (100% in haploid,
80% in diploid).
polymerase activity 35% petites in haploid yeast, only 2.5% in diploid.
ced catalytic activity, low kcat
tly reduced gap-ﬁlling activity Mild increase of petites in haploid yeast
old more active than WT Temperature sensitive mutant in yeast, high petite
frequency at 36 °C.
er polymerase activity than WT
Fig. 5. An overview of what is currently known about POLG mutations from experimental studies.
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gap-ﬁlling activity (107–139% compared to WT). E900G also
demonstrated a modifying effect, as the A692T-E900G Mip1
double mutant had a slightly higher gap-ﬁlling activity than
A692T (30–40% compared to WT) [35]. However, E900G increased
petite frequency approximately 2-fold, and presented a tempera-
ture-sensitive phenotype with a higher petite frequency at 36 °C
as compared to 28 °C.
6. POLG mutations associated with susceptibility to NRTI toxicity
In 2007, the ﬁrst POLG mutation associated with mitochondrial
toxicity as a result of NRTI therapy was reported [36]. NRTIs are chain
terminators that are used to inhibit replication of viruses such as HIV-
1. Mitochondrial toxicity has been associated with the use of NRTIs,
both in treated human patient populations, as well as in animal and
human studies of toxicity [37, 38]. In vitro studies by our group
showed that NRTIs can inhibit the enzymatic activities of DNA
polymerase γ, but at different levels [39].
Yamanaka and colleagues identiﬁed an HIV-1 infected patient
with a history of hyperlactatemia induced by d4T treatment [36].
Sequencing analysis of the POLG gene in this patient identiﬁed a
homozygous R964C mutation. The R964C mutation was recently
identiﬁed in trans with A862C in a patient with ataxia–neuropathy
syndrome [28]. Yamanaka and colleagues also overexpressed and
puriﬁed R964C p140 from baculovirus-infected silkworms [36]. The
recombinant R964C p140 had only 14% polymerase activity
compared to WT [36]. Ratios of mtDNA to nuclear DNA were
measured in order to determine mtDNA copy number in lympho-
blastoid cells from the index patient, the index patient's unaffected
heterozygous niece, and three patients who had long term d4T use
as controls (two out of three patient controls had normal lactate
levels). Lymphoblastoid cells from the index patient and her niece
showed the most severe decrease in mtDNA copy number after
treatment with 10 μM d4T. This suggests that pol γ containing the
R964C mutation is not normally deleterious, but certain conditions
(such as NRTI treatment), may push mitochondrial function below
the clinical threshold, causing mitochondrial disease.
7. Analysis of other POLG mutations in yeast
Barufﬁni et al. recently analyzed several other mutations in the
MIP1 gene that correspond to disease mutations in human POLG[19, 35]. These mutations were assayed for petite formation,
mtDNA mutation frequency and polymerase activity from mito-
chondrial extracts. The yeast mip1-G224A allele, equivalent to the
human POLG G268A substitution associated with autosomal
recessive PEO, produced a 2.5-fold increase in petite frequency
and a 10-fold increase in point mutations as measured by
erythromycin resistant mutants in haploid cells [19]. However,
this effect was repressed to WT levels in heterozygous diploid cells
indicative of the recessive nature of this mutation. Similar to their
observation with the mip1-Y757C mutation, the petite frequency by
the mip1-G224A allele decreased with either over-expression of
RNR1 or treatment with dihydrolipoic acid [19].
In haploid yeast strains, the G651S, A692T and H734Y Mip1
alleles (corresponding to G848S, A889T and H932Y in human
POLG, respectively) produced petite frequencies of 46%, 17%
and 98%, respectively, at 28 °C, which increased at 36 °C [35].
A fourth mutation, G807R (corresponding to G1051R in human
POLG) caused only a mild increase in petite frequency
compared to the other mutations, and displayed a 4 to 5-fold
increase in petites at 36 °C. Interestingly, G651S had high
mtDNA instability and signiﬁcantly increased mutation fre-
quency as measured in the erythromycin resistance assay [35].
Gap-ﬁlling activities in mitochondrial extracts from yeast
strains overexpressing these proteins were measured and all
showed reduced levels of gap-ﬁlling activity in the range of
30–85% of WT Mip1 protein [35].
8. The POLG CAG trinucleotide repeat
Near the N-terminus of the mature human DNA polymerase is
a stretch of 13 glutamine residues encoded by ten CAG codons
followed by one CAA codon and two additional CAG codons [9].
This CAG trinucleotide stretch is not found in other eukaryotic
POLG genes with the exception of the African great apes, where
the length of the CAG repeat is species-speciﬁc [40]. POLG CAG
repeat variants are associated with idiopathic sporadic Parkinson's
disease [41] and testicular cancer [42, 43]. POLG CAG repeat
variants have also been associated with male infertility [44, 45],
although some studies reported alterations in the CAG trinucleo-
tide tract of POLG at the same frequency in both normal and
infertile men [46–49]. However, studies using human cells with a
deletion of the CAG repeat showed no detectable effect on
mitochondrial function in tissue culture cells [50]. The role of the
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more studies are needed.
9. The accessory subunit of DNA polymerase γ
The ﬁrst POLG2 mutation associated with disease was discovered
in 2006 [15]. The heterozygous G451E mutation was identiﬁed in a
patient presenting with adPEO with multiple mtDNA deletions and
cytochrome c oxidase-deﬁcient muscle ﬁbers. This mutation was not
seen in 100 PEO patient samples or in 288 control chromosomes.
Biochemical characterization of puriﬁed, recombinant G451E-sub-
stituted accessory subunit protein in vitro revealed incomplete
stimulation of the catalytic subunit due to weak subunit interaction,
as shown by immunoprecipitation experiments, N-ethylmaleimide
protection assays, processivity, and primer extension assays. The
G451E accessory subunit protein retained normal DNA binding
function as measured by single-stranded DNA cellulose chromato-
graphy, but failed to enhance DNA-binding strength of the p140–p55
holoenzyme complex. In vivo, the disease most likely arises through
haplotype insufﬁciency or heterodimerization of the mutated andWT
proteins, which promote mtDNA deletions by stalling the DNA
replication fork. The progressive accumulation of mtDNA deletions
produces cytochrome c oxidase deﬁciency in muscle ﬁbers and results
in the clinical phenotype.
G416A is the second POLG2 variation associated with a mitochon-
drial disease patient [51]. This patient presented with hearing loss,
PEO, loss of central vision, macrocytic anemia, and hypogonadism.
Analysis of the G416A protein revealed WT-like p55 function as
displayed by normal chromatographic properties, stimulation of
processive DNA synthesis for pol γ, and normal protection of the
catalytic subunit by N-ethylmaleimide. The G416A accessory subunit
protein did not have signiﬁcantly impaired enzyme function,
suggesting that it was unlikely to be the cause of pathogenesis.
Further sequencing of mitochondrial disease loci revealed a novel
Y582C mutation in the OPA1 gene (encoding a dynamin-related
GTPase, mutations inwhich are more commonly associated with optic
atrophy, Fig. 1). The authors concluded that the mutation in OPA1may
better explain the patient's causative features of disease. The latest
data at NCBI now identiﬁes G416A in POLG2 as a polymorphism
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17850455), sug-
gesting it is more likely that the novel OPA1 mutation in this patient
could be contributing to their mitochondrial disease status.
10. Closing remarks
Sequencing the POLG gene in patients with mitochondrial
disease is helpful for conﬁrming the diagnosis of mitochondrial
disease, especially in the case of Alpers syndrome. POLG sequencing
offers the added beneﬁts of carrier testing, prenatal diagnosis,
postnatal pre-symptomatic diagnosis of siblings and optimized
clinical management from the early stages of disease. In a recent
study by Wong et al., the majority (92.5%) of mutated alleles in
various populations were missense mutations, while frameshift and
nonsense mutations accounted for a smaller fraction (7.5%) of the
overall mutated alleles [28]. However, several newly identiﬁed
mutations in mitochondrial disease patients may be neutral
polymorphisms. For example, in the Wong et al. study, 44% (27/
61) of the mitochondrial disease patients with a POLG mutation
had only one allele affected that was not consistent with autosomal
dominant inheritance [28]. As a result, the molecular diagnosis of
these 27 patients was unclear, either suggesting locus hetero-
geneity (Fig. 1), undetected mutations outside of the POLG coding
region (such as the intronic or promoter regions), or environ-
mental factors. Digenic effects have been identiﬁed previously, for
example, in a PEO patient with recessive mutations in both POLG
and the mtDNA helicase [52].Despite the increasing level of knowledge on pol γ mutations in
disease (Table 1; Fig. 5), there is still much to learn. A three-
dimensional structure of the pol γ holoenzymewill be very instructive
for identifying more contacts between the subunits of pol γ, and will
provide a better understanding of these disease mutations. Addition-
ally, knowledge of the holoenzyme structure will be essential for the
rational development of new NRTIs, to determine whether the new
drug causes inhibition of the holoenzyme. We still have much to learn
about the role of POLG mutations in parkinsonism, Charcot–Marie–
Tooth disease, and male infertility. Why do some mutations cause
mtDNA deletions, whereas others cause depletion or point mutations
inmtDNA? Furthermore, factors such as tissue speciﬁcity, age of onset,
and the effect of environmental factors have not yet been resolved.
Analysis of pol γ should enable a greater understanding of mtDNA
replication and the role of defective mtDNA replication proteins in
disease.
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